Genvec Inc (NASDAQ:GNVC)

CAPS Rating: 1 out of 5

A biopharmaceutical company, which develops novel gene-based therapeutic drugs and vaccines.

Results 1 - 20 of 43 : 1 2 3 Next »

Recs

1
Member Avatar USMCbeendoinit (< 20) Submitted: 7/13/2011 4:56:21 AM : Outperform Start Price: $3.24 GNVC Score: -127.16

I have been doin some research on GenVec and from what I am seeing, GV is headed in the right direction. With the new addition of Doctor Mahmoud and Doctor Connor to the board of directors, I am feeling really confident in the management of this company. Even though TNFerade (GenVecs Pancreatic Cancer fighting machine) ,wich was saposed to be released as GV's staple product, failed Phase III testing (Due to only an 8% gain in patients life expectancy), GV still has huge potential to release something big. Do your research on their current projects and you wont be let down!

Recs

0
Member Avatar Guitarmaniatico (< 20) Submitted: 2/19/2010 2:59:47 PM : Outperform Start Price: $24.20 GNVC Score: -167.01

This company is doing things very well, good balance sheets and very strong income and dividend too!!

Recs

1
Member Avatar mwrcbp (< 20) Submitted: 2/13/2010 8:40:00 PM : Outperform Start Price: $21.50 GNVC Score: -170.37

GENVEC offers a Dynamic pipeline:
Product Programs include

TNFerade™ for Pancreatic Cancer -late stage trial
TNFerade™ for Head and Neck Cancer
Vaccines
HIV Vaccine
Malaria Vaccine
Foot and Mouth Disease
Hearing & Balance Loss -Partnership w/Novartis

Do your DD, Genvec may have the key to the first FDA approved Gene Therapy for Cancer in TNFERADE!!

Recs

0
Member Avatar ElginBaylorkt (< 20) Submitted: 1/19/2010 10:09:31 PM : Outperform Start Price: $19.60 GNVC Score: -161.96

Must have something...

Recs

1
Member Avatar mark54g (< 20) Submitted: 1/8/2010 8:06:11 AM : Outperform Start Price: $16.10 GNVC Score: -161.98

I have had GNVC since it was sub 80 cents. The reports are coming out in the near future on whether TNFerade will be the break out drug against solid/non vascular cancers. I believe Pancreatic cancer was chosen for the platform arrangement because of how quickly it moves. The indications for Head and Neck cancer as well as possible skin cancers and other solid tumors will likely result in a partnership. The other pipeline therapies they have, for things like Malaria and hearing loss will also likely keep them going for a while. They may need to make another offering shortly, but not if a partnership is announced.

Recs

2
Member Avatar Sqwii (< 20) Submitted: 6/1/2008 3:16:21 PM : Outperform Start Price: $18.00 GNVC Score: -136.67

In recent clincal trials, Genvec's leading drug TNFerade (TM) has received very encouraging results for head,neck & esophageal cancers. For more information, please go to the companys web site: www.genvec.com The target price of $20.00 could be met from one month to within three years.

Recs

0
Member Avatar slaveofthegov (50.05) Submitted: 5/30/2008 10:56:49 AM : Outperform Start Price: $17.90 GNVC Score: -136.20

Got in with real money at 1.75 based on what they have in the pipeline.

Recs

1
Member Avatar kporter007 (< 20) Submitted: 2/27/2008 10:30:50 AM : Outperform Start Price: $28.40 GNVC Score: -127.27

They are in third phase trials for their main product which had promising results last year. This year they got the FDA to allow them to change the wording of the goal of the trials from 12month survival rate to overall survival rate, which is much more in line with their initial results (which showed a 10 month survival increase if I remember correctly). This should allow their trials to be successful and streamline FDA approval.

They also inked a deal with a UK company to mass produce the Adenovector that is their main product. This shows me that they are expecting approval for the pancreatic treatment and are getting everything ready to roll out the product.

This same treatment is also being tested for other types of cancers.

They also have contracts with government and world organizations for vaccines for malaria and AIDS, plus are developing a treatment for hearing and balance loss.

I think that if (and I suspect it will) their first product for pancreatic cancer is approved and starts to sell, then the other cancer treatments will not be far behind.

I bought this in the $3 range (I have lost 50%), but it is a long hold. I expect to start seeing a turn around towards the end of summer 08, with a large increase in the 1st quarter 09 based on when I believe approval and manufacturing will begin.

Recs

0
Member Avatar glfraley (99.46) Submitted: 1/24/2008 11:58:54 AM : Outperform Start Price: $15.40 GNVC Score: -142.45

Long term pick here, the ups and downs over the short term are going to be the results of day traders looking to make a few cents a share on hundreds of thousands of shares.

These guys look very promising and am consifdering purchasing the stock with LTBH in mind.

Recs

1
Member Avatar hondo928 (99.35) Submitted: 11/7/2007 8:00:20 PM : Outperform Start Price: $22.00 GNVC Score: -130.83

Well because I'm getting it so much cheaper than everyone else. And they are increasing cash flow.

Recs

0
Member Avatar stockguy07 (< 20) Submitted: 10/25/2007 5:19:16 PM : Outperform Start Price: $25.00 GNVC Score: -126.69

sudnwealth, IV

Recs

0
Member Avatar BUBBUP (< 20) Submitted: 6/6/2007 1:16:57 PM : Outperform Start Price: $34.90 GNVC Score: -129.30

I like the price and the market that GNVC is after.

Recs

0
Member Avatar AFKCobra (< 20) Submitted: 6/4/2007 7:07:39 PM : Outperform Start Price: $34.50 GNVC Score: -127.83

Today's news of the ASCO conference caused a 30% drop in the GNVC stock price. I believe that the company will figure out why the trials were unsuccessful. Like Edison and his filaments, the "light" will come on for GenVec.

Recs

0
Member Avatar sbrooks64 (< 20) Submitted: 4/14/2007 8:10:30 AM : Outperform Start Price: $41.30 GNVC Score: -135.07

this stock will continue to rise. It has contracts with the Navy and other services that will bring in revenue look for this stock to take off

Recs

0
Member Avatar adbb (< 20) Submitted: 4/14/2007 8:00:36 AM : Underperform Start Price: $41.30 GNVC Score: +135.07

Went up too fast. Wait a few months until it consolidates down in the $2 range.

Recs

0
Member Avatar bioeng (44.71) Submitted: 4/13/2007 8:08:09 PM : Outperform Start Price: $41.30 GNVC Score: -135.07

The Vaccines they are developing with the navy ie malira and the HIV will push this company.

Recs

0
Member Avatar SamPena1 (< 20) Submitted: 4/13/2007 1:34:16 PM : Outperform Start Price: $42.30 GNVC Score: -135.86

Good product & management.

Recs

0
Member Avatar xhan2 (< 20) Submitted: 4/12/2007 8:50:13 PM : Outperform Start Price: $40.50 GNVC Score: -135.94

its great

Recs

0
Member Avatar marubixcube (< 20) Submitted: 4/4/2007 1:59:04 PM : Outperform Start Price: $36.70 GNVC Score: -136.90

Good products in the pipeline. Wait and see.

Recs

2
Member Avatar IPstockRet (< 20) Submitted: 4/3/2007 1:49:36 PM : Outperform Start Price: $33.18 GNVC Score: -136.53

Good business model, market niche and business practices. Joining a completive industry but with government ties. Products show positive results. Management is strong and not flipping.

Results 1 - 20 of 43 : 1 2 3 Next »

Featured Broker Partners